Biotech News
Immutep Further Expands United States Patent Estate for Efti-Based Combination Therapies
Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,788,796) entitled “ Combined Preparations for the Treatment of Cancer or Infection ” by the United States Patent and Trademark Office (USPTO).
